Description: Gland Pharma Limited, a generic injectable-focused company, engages in the development, manufacture, sale, and distribution of pharmaceuticals. The company's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its products for various therapeutic categories, such as anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, gastro-intestinal, hormones and related drugs, fertility supplements, Gnrh agonists and antagonists, as well as anti-neoplastic, gynecological, neurological and central nervous system, respiratory, blood related, ophthalmological and otological, pain/analgesics, vitamins/minerals/nutrients, and others. The company also provides contract development services. It sells its products primarily under a business-to-business model in the United States, Europe, Canada, Australia, India, and internationally. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited is a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Home Page: www.glandpharma.com
Plot No. 11 & 84, TSIIC Phase: IV
Hyderabad,
502307
India
Phone:
91 84 5569 9999
Officers
| Name | Title |
|---|---|
| Mr. Srinivas Sadu | MD, CEO & Director |
| Mr. Ravi Shekhar Mitra | Chief Financial Officer |
| Mr. Sampath Kumar Pallerlamudi | Company Sec. & Compliance Officer |
| Mr. Ashish Adhikari | VP of Operations |
| Mr. K. V.G.K. Raju | Chief Technical Officer |
| Mr. Sumanta Bajpayee | VP of Investor Relations |
| Mr. Susheel Ogra | Sr. Gen. Mang. of Sales & Marketing |
| Ms. Shilpi Sahay | Deputy Gen. Mang. of HR |
| Dr. C. S. Venkatesan | Sr. VP of R&D |
| Dr. Surapanini Sridevi | Sr. VP of R&D |
Exchange: NSE
Country: IN
Currency: Indian Rupee (INR)
| Forward PE: | 51.2821 |
|---|---|
| Trailing PE: | 25.3681 |
| Price-to-Book MRQ: | 3.7166 |
| Price-to-Sales TTM: | 7.0838 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 4639 |